Loading...
•
Sep 30, 2020
Surmodics Q4 2020 Earnings Report
Revenue decreased by 27% year-over-year and GAAP EPS resulted in ($0.22).
Key Takeaways
Surmodics reported a decrease in revenue for the fourth quarter of fiscal year 2020, with a GAAP loss per share. The company received FDA clearance for its PounceTM Thrombus Retrieval System.
Revenue of $22.5 million, a decrease of 27% year-over-year
GAAP EPS of ($0.22), non-GAAP EPS of ($0.18)
FDA clearance received for PounceTM Thrombus Retrieval System for non-surgical removal of clots from the peripheral arterial vasculature
Cash from operating activities totaled $1.3 million
Revenue by Segment
Forward Guidance
Due to the continued uncertainty surrounding the duration and magnitude of the COVID-19 pandemic, the Company will not provide financial guidance at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...